Drug Profile
Research programme: osteoarthritis therapeutics - ProStrakan/TiGenix
Alternative Names: BMP activators - ProStrakan/TiGenix; Bone morphogenetic protein activators - ProStrakan/TiGenixLatest Information Update: 03 Aug 2018
Price :
$50
*
At a glance
- Originator ProStrakan; TiGenix
- Class Small molecules
- Mechanism of Action Bone morphogenetic protein activators; Osteoblast stimulants; Osteogenesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Osteoarthritis
Most Recent Events
- 31 Jul 2018 TiGenix has been acquired by Takeda
- 19 Apr 2006 Preclinical development is ongoing